William Blair Brokers Decrease Earnings Estimates for WST

West Pharmaceutical Services, Inc. (NYSE:WST) – Analysts at William Blair lowered their Q3 2025 earnings per share (EPS) estimates for shares of West Pharmaceutical Services in a research report issued to clients and investors on Friday, April 25th. William Blair analyst M. Larew now anticipates that the medical instruments supplier will post earnings of $1.60 per share for the quarter, down from their prior forecast of $1.68. The consensus estimate for West Pharmaceutical Services’ current full-year earnings is $6.62 per share. William Blair also issued estimates for West Pharmaceutical Services’ Q4 2025 earnings at $1.69 EPS, Q1 2026 earnings at $1.59 EPS, Q2 2026 earnings at $1.74 EPS, Q3 2026 earnings at $1.83 EPS and Q4 2026 earnings at $1.93 EPS.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings results on Thursday, April 24th. The medical instruments supplier reported $1.45 earnings per share for the quarter, beating the consensus estimate of $1.22 by $0.23. The company had revenue of $698.00 million during the quarter, compared to the consensus estimate of $685.24 million. West Pharmaceutical Services had a net margin of 17.03% and a return on equity of 18.60%. The firm’s quarterly revenue was up .4% compared to the same quarter last year. During the same quarter last year, the firm earned $1.56 earnings per share.

Several other equities research analysts have also recently issued reports on WST. Stephens upgraded shares of West Pharmaceutical Services to a “strong-buy” rating in a report on Monday, April 21st. StockNews.com downgraded West Pharmaceutical Services from a “buy” rating to a “hold” rating in a research note on Thursday, February 27th. KeyCorp cut their price objective on West Pharmaceutical Services from $470.00 to $325.00 and set an “overweight” rating for the company in a report on Friday, February 14th. Evercore ISI initiated coverage on West Pharmaceutical Services in a report on Tuesday, March 18th. They issued an “outperform” rating and a $275.00 target price on the stock. Finally, Citigroup started coverage on West Pharmaceutical Services in a research note on Wednesday, January 8th. They set a “buy” rating and a $400.00 price target for the company. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, West Pharmaceutical Services currently has an average rating of “Moderate Buy” and a consensus price target of $332.50.

West Pharmaceutical Services Stock Performance

Shares of NYSE WST opened at $216.51 on Monday. The firm’s 50-day moving average price is $218.17 and its 200-day moving average price is $283.19. West Pharmaceutical Services has a 52-week low of $187.43 and a 52-week high of $372.79. The company has a market cap of $15.65 billion, a PE ratio of 32.36, a PEG ratio of 6.74 and a beta of 1.22. The company has a quick ratio of 2.23, a current ratio of 2.79 and a debt-to-equity ratio of 0.08.

Institutional Investors Weigh In On West Pharmaceutical Services

A number of institutional investors have recently bought and sold shares of WST. Fiera Capital Corp boosted its stake in shares of West Pharmaceutical Services by 13.2% in the fourth quarter. Fiera Capital Corp now owns 140,893 shares of the medical instruments supplier’s stock worth $46,151,000 after acquiring an additional 16,418 shares during the period. Trust Point Inc. boosted its stake in West Pharmaceutical Services by 321.0% in the 4th quarter. Trust Point Inc. now owns 3,183 shares of the medical instruments supplier’s stock worth $1,043,000 after purchasing an additional 2,427 shares during the period. Savant Capital LLC grew its holdings in West Pharmaceutical Services by 15.0% during the 4th quarter. Savant Capital LLC now owns 1,003 shares of the medical instruments supplier’s stock valued at $329,000 after buying an additional 131 shares in the last quarter. Avanza Fonder AB purchased a new stake in West Pharmaceutical Services during the 4th quarter valued at approximately $2,553,000. Finally, Tokio Marine Asset Management Co. Ltd. raised its position in shares of West Pharmaceutical Services by 904.2% during the fourth quarter. Tokio Marine Asset Management Co. Ltd. now owns 21,941 shares of the medical instruments supplier’s stock valued at $7,187,000 after buying an additional 19,756 shares during the last quarter. Hedge funds and other institutional investors own 93.90% of the company’s stock.

West Pharmaceutical Services Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 6th. Stockholders of record on Wednesday, July 30th will be paid a $0.21 dividend. The ex-dividend date of this dividend is Wednesday, July 30th. This represents a $0.84 dividend on an annualized basis and a dividend yield of 0.39%. West Pharmaceutical Services’s dividend payout ratio (DPR) is presently 13.19%.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.